Managing Sickle Cell Disease (managingscd.com) is the newest member of the MediCom Worldwide, Inc., suite of hematology websites. The goals of this growing virtual community are to provide education, tools and resources for clinicians who provide care for patients with the disease and serve as a place for engaged, on-demand learning and collaboration using multiple interactive formats.
|Mitapivat Granted Orphan Drug Designation for Treatment of Sickle Cell Disease
On November 12, 2020, Agios Pharmaceuticals announced that that the US Food and Drug Administration granted orphan drug designation to mitapivat, an investigational first-in-class pyruvate kinase R (PKR) activator, for treatment of sickle cell disease.
To read the press release, click here